AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $1.68 billion. The enterprise value is $1.67 billion.
| Market Cap | 1.68B |
| Enterprise Value | 1.67B |
Important Dates
The next estimated earnings date is Tuesday, September 1, 2026, after market close.
| Earnings Date | Sep 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 29.61 million shares outstanding. The number of shares has decreased by -3.66% in one year.
| Current Share Class | 29.61M |
| Shares Outstanding | 29.61M |
| Shares Change (YoY) | -3.66% |
| Shares Change (QoQ) | -8.46% |
| Owned by Insiders (%) | 2.57% |
| Owned by Institutions (%) | 78.65% |
| Float | 20.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 31.83 |
| PS Ratio | 7.22 |
| Forward PS | 23.02 |
| PB Ratio | 129.11 |
| P/TBV Ratio | 131.68 |
| P/FCF Ratio | 380.70 |
| P/OCF Ratio | 374.83 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 40.38, with an EV/FCF ratio of 378.64.
| EV / Earnings | n/a |
| EV / Sales | 7.18 |
| EV / EBITDA | 40.38 |
| EV / EBIT | 40.92 |
| EV / FCF | 378.64 |
Financial Position
The company has a current ratio of 7.58, with a Debt / Equity ratio of 21.76.
| Current Ratio | 7.58 |
| Quick Ratio | 7.49 |
| Debt / Equity | 21.76 |
| Debt / EBITDA | 6.33 |
| Debt / FCF | 62.91 |
| Interest Coverage | 0.49 |
Financial Efficiency
Return on equity (ROE) is -114.55% and return on invested capital (ROIC) is 7.61%.
| Return on Equity (ROE) | -114.55% |
| Return on Assets (ROA) | 6.78% |
| Return on Invested Capital (ROIC) | 7.61% |
| Return on Capital Employed (ROCE) | 14.17% |
| Weighted Average Cost of Capital (WACC) | 8.89% |
| Revenue Per Employee | $2.23M |
| Profits Per Employee | -$257,567 |
| Employee Count | 104 |
| Asset Turnover | 0.62 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AnaptysBio has paid $160,000 in taxes.
| Income Tax | 160,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +186.46% in the last 52 weeks. The beta is 0.40, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | +186.46% |
| 50-Day Moving Average | 58.23 |
| 200-Day Moving Average | 54.24 |
| Relative Strength Index (RSI) | 49.02 |
| Average Volume (20 Days) | 412,713 |
Short Selling Information
The latest short interest is 5.40 million, so 18.24% of the outstanding shares have been sold short.
| Short Interest | 5.40M |
| Short Previous Month | 5.00M |
| Short % of Shares Out | 18.24% |
| Short % of Float | 26.83% |
| Short Ratio (days to cover) | 6.74 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $232.39 million and -$26.79 million in losses. Loss per share was -$0.95.
| Revenue | 232.39M |
| Gross Profit | 103.61M |
| Operating Income | 40.80M |
| Pretax Income | -26.63M |
| Net Income | -26.79M |
| EBITDA | 41.34M |
| EBIT | 40.80M |
| Loss Per Share | -$0.95 |
Balance Sheet
The company has $286.46 million in cash and $277.36 million in debt, with a net cash position of $9.10 million or $0.31 per share.
| Cash & Cash Equivalents | 286.46M |
| Total Debt | 277.36M |
| Net Cash | 9.10M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 12.75M |
| Book Value Per Share | 0.44 |
| Working Capital | 274.41M |
Cash Flow
In the last 12 months, operating cash flow was $4.48 million and capital expenditures -$69,000, giving a free cash flow of $4.41 million.
| Operating Cash Flow | 4.48M |
| Capital Expenditures | -69,000 |
| Depreciation & Amortization | 543,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 4.41M |
| FCF Per Share | $0.15 |
Margins
Gross margin is 44.58%, with operating and profit margins of 17.56% and -11.53%.
| Gross Margin | 44.58% |
| Operating Margin | 17.56% |
| Pretax Margin | -11.46% |
| Profit Margin | -11.53% |
| EBITDA Margin | 17.79% |
| EBIT Margin | 17.56% |
| FCF Margin | 1.90% |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.66% |
| Shareholder Yield | 3.66% |
| Earnings Yield | -1.60% |
| FCF Yield | 0.26% |
Analyst Forecast
The average price target for AnaptysBio is $87.09, which is 53.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $87.09 |
| Price Target Difference | 53.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 9.43% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of 0.43 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.43 |
| Piotroski F-Score | 6 |